The Foundation 30
What Is Foundation 30™?
Foundation 30™ is a 30-day structured research protocol designed as an intentional entry point into metabolic signaling and mitochondrial communication research.
This protocol combines Retatrutide and MOTS-c, two research compounds studied across complementary areas of metabolic biology. Retatrutide is investigated for triple-receptor metabolic signaling through GLP-1, GIP, and glucagon pathways, while MOTS-c is studied as a mitochondrial-derived peptide involved in cellular energy sensing, AMPK-related signaling, and metabolic adaptation.
Rather than combining unnecessary compounds, Foundation 30™ focuses on two core research layers: systemic metabolic receptor activity and intracellular mitochondrial energy communication.
Foundation 30™ was built for researchers who want a cleaner, more structured starting point for observing metabolic pathway interaction over a defined 30-day research window.
Certificate of Analysis
Third-party testing documentation available for purity and analytical verification.
Foundation 30™ Research Overview
Foundation 30™ is the entry-level protocol within the Purple Protocol System™, created for structured metabolic signaling research.
This 30-day protocol includes:
The protocol is designed around a simple principle: start with structure, not guesswork.
By pairing a triple-receptor metabolic signaling compound with a mitochondrial-derived peptide, Foundation 30™ provides a focused research framework for studying how systemic hormone-receptor activity and cellular energy-response pathways may interact in controlled research settings.
Why the Foundation Protocol Exists
Many research protocols begin with complex stacks before baseline signaling behavior is clearly understood. Foundation 30™ was developed to create a more intentional starting point.
The goal is not to overload the model with multiple compounds. The goal is to observe two foundational systems:
- Metabolic receptor signaling
- Mitochondrial energy communication
Foundation 30™ was built for research involving glucose-response models, appetite-related signaling, energy regulation, substrate utilization, AMPK-related pathways, mitochondrial responsiveness, and whole-system metabolic stability.
The Science Behind the Stack
Retatrutide
Retatrutide, also known as LY3437943, is studied as a triple GLP-1, GIP, and glucagon receptor agonist. These receptor systems are associated with incretin biology, glucose regulation, insulin-response pathways, glucagon-related energy signaling, lipid metabolism, appetite-related pathways, and systemic energy balance.
In research settings, triple-agonist compounds are often examined because they allow researchers to study broader metabolic pathway engagement compared with single-receptor or dual-receptor models.
Within Foundation 30™, Retatrutide represents the systemic receptor-signaling component of the protocol.
MOTS-c
MOTS-c is a 16–amino acid mitochondrial-derived peptide encoded within mitochondrial DNA. It is studied for its relationship with cellular energy sensing, AMPK-dependent signaling, glucose metabolism, insulin-sensitivity models, mitochondrial-to-nuclear communication, and adaptive stress-response pathways.
Research models often examine MOTS-c in the context of metabolic flexibility, skeletal-muscle energy signaling, cellular response to nutrient stress, and age-related metabolic adaptation.
Within Foundation 30™, MOTS-c represents the mitochondrial and intracellular energy-communication component of the protocol.
Why These Two Compounds Are Paired
Metabolic regulation does not occur through one pathway alone.
Retatrutide is studied for systemic receptor-level signaling through GLP-1, GIP, and glucagon pathways.
MOTS-c is studied for mitochondrial and intracellular energy communication, especially pathways related to AMPK activation, glucose utilization, and metabolic stress adaptation.
Together, they create a focused two-layer research framework:
- Systemic metabolic signaling
- Cellular energy responsiveness
Foundation 30™ was not built to be the most advanced stack. It was built to be the most intentional first step: controlled, purposeful, and easier to observe in a structured research environment.
Research Applications
Foundation 30™ may be useful in controlled research models focused on:
- Entry-level metabolic signaling research
- Triple-receptor pathway observation
- Mitochondrial communication models
- Glucose-response pathway research
- Energy-balance signaling
- AMPK-related cellular adaptation
- Metabolic flexibility research
- Short-duration protocol observation
- Baseline response tracking before more complex protocol designs
What Researchers May Document
In controlled research environments, Foundation 30™ may be used in protocols where researchers document broad biological patterns over time, including:
- Appetite-pattern observations
- Energy-stability notes
- Craving-related behavior patterns
- Metabolic-response markers
- Recovery-related observations
- Training-response models
- Body-composition trends
- Sleep and rhythm-related notes
- General protocol consistency
The goal of Foundation 30™ is not intensity. The goal is stability, clarity, and structured observation.
The Purple Standard™
Every vial included in Foundation 30™ is handled according to the Purple Standard™. This includes third-party testing, purity verification, controlled storage conditions, batch tracking, and internal rejection of any lot that does not meet required quality thresholds.
The Purple Standard™ exists to support consistency, documentation, and research confidence across every Purple Protocol™.
Investigational Research Context
Foundation 30™ should be considered an investigational research protocol. Available scientific literature primarily examines Retatrutide and MOTS-c individually or in related research contexts. Findings should not be interpreted as approved therapeutic, clinical, veterinary, or human-use outcomes for this protocol.
This product is supplied for laboratory research only and is not intended for human consumption, clinical use, veterinary use, diagnostic use, or self-experimentation.
Scientific References
View References
Retatrutide Research
- Coskun T. et al. (2022) — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.
- Urva S. et al. (2022) — LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b randomized trial.
- Jastreboff A.M. et al. (2023) — Triple-hormone-receptor agonist Retatrutide for obesity.
- Rosenstock J. et al. (2023) — Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes.
- Sanyal A.J. et al. (2024) — Triple hormone receptor agonist Retatrutide for metabolic dysfunction-associated steatotic liver disease.
MOTS-c Research
- Lee C. et al. (2015) — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
- Lee C., Yen K., Cohen P. (2016) — MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism.
- Kim K.H. et al. (2018) — The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.
- Reynolds J.C. et al. (2021) — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
- Wan W. et al. (2023) — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism, and aging.
- Zheng Y. et al. (2023) — MOTS-c: a promising mitochondrial-derived peptide for metabolic and aging-related research.
Need Help?
